October 23, 2025 – (Investorideas.com Newswire), a leading investment platform for biotech and medtech stocks, releases a news and trading alert for SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing greater value to patients, physicians and healthcare providers through the development, commercialization and distribution of new specialty products that address unmet market needs.
The stock joins the Nasdaq list of top gainers today after news of
Commercial sales and fulfillment of first orders for Arbli. The stock is trading at $1.3200, +0.7485, gaining over 129% on volume of over 497 million shares as of this report. The stock has a morning high of $1.72.
News overview
SCIENTURE Holdings, Inc. (NASDAQ: SCNX), a pharmaceutical company focused on innovative specialty products, announced on October 23, 2025 the launch of commercial sales and fulfillment of initial customer orders for Arbli™ (losartan potassium) oral suspension, 10 mg/ml. This is the first FDA-approved ready-to-use oral suspension formulation of losartan, providing a convenient alternative to solid dosage forms for patients with swallowing difficulties. Arbli™ addresses an approximately $256 million annual U.S. market with more than 71 million prescriptions and addresses unmet hypertension treatment needs in retail, institutional and long-term care settings.
To drive adoption, SCIENTURE initiated a multi-channel promotional campaign and secured major PBM-led group purchasing organization (GPO) agreements, expanding access to more than 2,500 healthcare facilities nationwide. “The start of commercial sales for Arbli™ represents a major achievement as we transition from development to execution,” said Narasimhan Mani, president and co-CEO. Executive Chairman Shankar Hariharan added that the product “embodies our mission to deliver patient-centric solutions.” Looking ahead, the company plans targeted outreach to healthcare professionals to increase education, awareness and availability, potentially capturing a significant share of the institutional market.
Complete news
https://finance.yahoo.com/news/science-announces-start-commercial-sales-120500876.html
Research biotech and medical device/technology stocks on Investorideas.com
https://www.investorideas.com/BIS/
About Investorideas.com – Great investment ideas
Investorideas.com is the go-to platform for great investment ideas. From the latest stock news to the top-rated investing podcasts, we cover it all
Follow us on X @investorideas
Follow us on Facebook
https://www.facebook.com/Investorideas
Follow us on YouTube
https://www.youtube.com/c/Investorideas
Contact Investorideas.com
800-665-0411
Disclaimer/Disclosure: Our site does not recommend the purchase or sale of any stock, service or product. This is not investment advice: nothing on our sites should be construed as an offer or solicitation to buy or sell any products or securities. All investments involve risks and possible losses. More information about disclaimers: https://www.investorideas.com/About/Disclaimer.asp. Learn more about publishing your press release and our other news services and awards on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to the regulations of each country. Read Investorideas.com’s privacy policy: https://www.investorideas.com/About/Private_Policy.asp
#SCNX #tops #Nasdaq #news #commercial #sales #order #execution #Arbli